Successful Use of Bortezomib–Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma

Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): William D. Marrero, Alexis Cruz-Chacón, Christian Castillo, Fernando CabanillasAbstractPlasmablastic lymphoma (PBL) is an unusual disorder which shares some features with myeloma. The vast majority of cases have been reported in human immunodeficiency virus (HIV) positive patients. It usually presents in the oral cavity and is considered as an aggressive lymphoma with a very poor prognosis for which there is no standard of care. Despite treatment most of the patients have a suboptimal outcome. Here we present a case of PBL presenting in the parotid gland of an HIV negative patient who upon relapse responded well to a regimen that included bortezomib and lenalidomide, drugs with excellent activity in myeloma.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research